SCHEMBL617366

SCHEMBL617366

Nc1ncc(N2CCN(C(=O)COc3ccccc3)CC2)nc1C(=O)Nc1ccccn1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 6/20 0.53
KDM4E B2RXH2 3/20 0.53
KMT2A Q03164 2/20 0.47
MEN1 O00255 1/20 0.47
ATR Q13535 2/20 0.47
ALDH1A1 P00352 3/20 0.46
TSHR P16473 2/20 0.46
HSD17B10 Q99714 2/20 0.46
MAPK1 P28482 2/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
CPT2 P23786 1/20 0.46
CPT1A P50416 1/20 0.46
POLB P06746 1/20 0.45
ME2 P23368 1/20 0.44
ME1 P48163 1/20 0.44
ME3 Q16798 1/20 0.44
MAPT P10636 1/20 0.44
RECQL P46063 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL615406 0.90 GRM5 (0.57) GRM5KDM4EKMT2AMEN1ATR
SCHEMBL615951 0.87 GRM5 (0.55) GRM5KDM4EATRALDH1A1HSD17B10
SCHEMBL614416 0.87 GRM5 (0.53) GRM5KDM4EATRALDH1A1TSHR
SCHEMBL614964 0.84 GRM5 (0.57) GRM5KDM4EKMT2AATRALDH1A1
SCHEMBL617365 0.84 GRM5 (0.62) GRM5KDM4EKMT2AMEN1ATR
SCHEMBL615929 0.84 GRM5 (0.58) GRM5ATRALDH1A1MAPK1
SCHEMBL617715 0.84 GRM5 (0.61) GRM5KDM4EATRALDH1A1TSHR
SCHEMBL615928 0.84 GRM5 (0.64) GRM5ATRALDH1A1TSHRHSD17B10
SCHEMBL616485 0.83 HDAC1 (0.54) GRM5ATRRAB9A
SCHEMBL617820 0.83 GRM5 (0.59) GRM5KDM4EATRALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140113005-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-04-24 US disclosed
US-8410112-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-02 US disclosed
US-8410112-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-02 US disclosed
US-8410112-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-02 US disclosed
US-20120040020-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-16 US disclosed
US-20120040020-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-16 US disclosed
US-20120040020-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140113005-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK2, CHEK1 GRM5 3215/4885KDM4E 2868/4885KMT2A 2291/4885
US-20120040020-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK2, CHEK1 GRM5 3215/4885KDM4E 2868/4885KMT2A 2291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.